EyePoint, Inc. (EYPT) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Eyepoint, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.166 -- 00:00:05.033 Good morning. My name is Tawanda, and I'll be your conference operator today. 00:00:05.033 -- 00:00:10.160 At this time, I would like to welcome everyone to the IFORN First Quarter 2025 Financial 00:00:10.160 -- 00:00:14.085 Results and Recent Corporate Development Conference Call. 00:00:14.085 -- 00:00:18.311 There will be a question and answer session to follow at the completion of the prepared 00:00:18.311 -- 00:00:24.819 remarks. Please be advised that this call is being recorded at the company's request. 00:00:24.819 -- 00:00:29.646 I would now like to turn the call over to George Elston, Executive Vice President, and 00:00:29.646 -- 00:00:34.091 Chief Financial Officer of Affluent. Sir, you may begin. 00:00:34.091 -- 00:00:38.117 Thank you, and thank you all for joining us on today's conference call to discuss iPoint's 00:00:38.117 -- 00:00:42.883 first quarter 2025 financial results and recent corporate developments. 00:00:42.883 -- 00:00:47.469 With me today is Dr. Jay Duker, President and Chief Executive Officer of iPoint. 00:00:47.469 -- 00:00:51.594 Jay will begin with a review of recent corporate updates and discuss the ongoing clinical 00:00:51.594 -- 00:00:57.382 trials for review. I will close with commentary on the first quarter 2025 financial results, 00:00:57.382 -- 00:01:00.072 and we will then open the call for your questions. 00:01:00.072 -- 00:01:04.679 Earlier this morning, we issued a press release detailing our financial results and recent 00:01:04.679 -- 00:01:08.906 corporate developments. A copy of the release can be found in the Investor Relations 00:01:08.906 -- 00:01:13.390 tab on the company website, www.ipointpharma.com. 00:01:14.835 -- 00:01:18.881 Before we begin our formal comments, I'll remind y...